CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE

DRUG2 trials

Sponsors

European Myeloma Network B.V., Shanghai Changzheng Hospital

Conditions

Multiple MyelomaPOEMS Syndrome

Phase 2

Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

CompletedNCT01346787

European Myeloma Network B.V.Multiple Myeloma

Start: 2011-07-31End: 2023-05-31Updated: 2023-09-08

KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome

RecruitingNCT07652879

Shanghai Changzheng HospitalPOEMS Syndrome

Start: 2026-06-15End: 2028-01-01Target: 20Updated: 2026-06-17

Related Papers

Personalized prognostic model for multiple myeloma patients using continuous variables

Blood2025-11-03

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Haematologica2020-02-2715 citations

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Blood2019-11-132 citations

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

2019-06-2047 citations

Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs

Blood2018-11-29

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Blood2015-01-28739 citations

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Blood2014-05-23153 citations